Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children

Best Practice and Research: Clinical Haematology

Volumn 24, Issue 3, 2011, Pages 443-452

  Schlegel, Patrick ^a   Teltschik, Heiko Manuel ^a   Pfeiffer, Matthias ^a   Handgretinger, Rupert ^a   Schumm, Michael ^a   Koscielniak, Ewa ^e   Feuchtinger, Tobias ^a   Klingebiel, Thomas ^b   Bader, Peter ^b   Schlegel, Paul Gerhard ^c   Greil, Johann ^d   Lang, Peter ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e Department of Pediatric Hematology and Oncology   (Germany)

Author keywords

Interleukin 2; natural killer cell activity; prevention of relapse; T cell depleted stem cells; very high risk malignancies

Indexed keywords

INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APPLICATION SITE SWELLING; ARTICLE; CELL ACTIVITY; CELL COUNT; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; EWING SARCOMA; FATIGUE; FEMALE; FEVER; FLOW CYTOMETRY; FOLLOW UP; HAPLOTYPE; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LIVER FAILURE; LOW DRUG DOSE; MALE; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; PAIN; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD; SKIN REDNESS; STEM CELL TRANSPLANTATION; T CELL DEPLETION; TREATMENT DURATION;

EID: 80052973893     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2011.04.007     Document Type: Review

References (23)

1. B.R. Dey, and T.R. Spitzer Current status of haploidentical stem cell transplantation Br J Haematol 135 2006 423 437 (Pubitemid 44583409)
2. A.D. Hess Separation of GVHD and GVL Blood 115 2010 1666 1667
3. K.M. Sullivan, R. Storb, and C.D. Buckner Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms N Engl J Med 320 1989 828 834 (Pubitemid 19094702)
4. S.S. Farag, T.A. Fehniger, and L. Ruggeri Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect Blood 100 2002 1935 1947 (Pubitemid 35001221)
5. M.M. Pfeiffer, T. Feuchtinger, and H.M. Teltschik Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children Haematologica 95 2010 1381 1388
6. T. Feuchtinger, M. Pfeiffer, and A. Pfaffle Cytolytic activity of NK cell clones against acute childhood precursor-B-cell leukaemia is influenced by HLA class I expression on blasts and the differential KIR phenotype of NK clones Bone Marrow Transplant 43 2009 875 881
7. P. Lang, and R. Handgretinger Haploidentical SCT in children: an update and future perspectives Bone Marrow Transplant 2 42 Suppl 2008 S54 S59
8. R. Handgretinger, and P. Lang The history and future prospective of haplo-identical stem cell transplantation Cytotherapy 10 2008 443 451
9. S. Cooley, and D.S. Weisdorf Natural killer cells and tumor control Curr Opin Hematol 17 2010 514 521
10. M. Colonna, and J. Samaridis Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells Science 268 1995 405 408
11. J.S. Miller, S. Cooley, and P. Parham Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT Blood 109 2007 5058 5061 (Pubitemid 46827806)
12. J.S. Miller, Y. Soignier, and A. Panoskaltsis-Mortari Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood 105 2005 3051 3057
13. Z. Wu, and Y. Xu IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation J Mol Cell Biol 2 2010 217 222
14. H.E. Kohrt, A.B. Pillai, and R. Lowsky NKT cells, Treg, and their interactions in bone marrow transplantation Eur J Immunol 40 2010 1862 1869
15. D.V. Liu, L.M. Maier, and D.A. Hafler Engineered interleukin-2 antagonists for the inhibition of regulatory T cells J Immunother 32 2009 887 894
16. P. Lang, M. Pfeiffer, and R. Handgretinger Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children Bone Marrow Transplant 29 2002 497 502 (Pubitemid 34428718)
17. L.J. Burns, D.J. Weisdorf, and T.E. DeFor IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial Bone Marrow Transplant 32 2003 177 186 (Pubitemid 36903442)
18. E. Koscielniak, T.H. Klingebiel, and C. Peters Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group Bone Marrow Transplant 19 1997 227 231 (Pubitemid 27077477)
19. K.Y. Liu, Y.H. Chen, and D.H. Liu A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation Bone Marrow Transplant 42 2008 535 539
20. Olson NK cells mediate reduction of GvHD by inhibiting activated, alloreactive T cells while retaining GvT effects PMID: 20233969 Blood 2010 115 2010 4293 4430
21. T.R. Malek, and A.L. Bayer Tolerance, not immunity, crucially depends on IL-2 Nat Rev Immunol 4 2004 665 674 (Pubitemid 39223073)
22. L. Ruggeri, M. Capanni, and E. Urbani Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2002 2097 2100 (Pubitemid 34229476)
23. V. Bachanova, L.J. Burns, and D.H. McKenna Allogeneic natural killer cells for refractory lymphoma Cancer Immunol Immunother 59 2010 1739 1744